Keystone Financial Planning Inc. boosted its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 1.2% during the second quarter, Holdings Channel reports. The institutional investor owned 131,006 shares of the pharmaceutical company’s stock after buying an additional 1,514 shares during the period. GlaxoSmithKline PLC comprises 3.4% of Keystone Financial Planning Inc.’s investment portfolio, making the stock its 11th largest position. Keystone Financial Planning Inc.’s holdings in GlaxoSmithKline PLC were worth $5,649,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Bronfman E.L. Rothschild L.P. raised its position in GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 753 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 2,359 shares in the last quarter. Proficio Capital Partners LLC raised its position in GlaxoSmithKline PLC by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after buying an additional 1,990 shares in the last quarter. Heritage Trust Co purchased a new position in GlaxoSmithKline PLC during the first quarter worth approximately $123,000. Finally, Westwood Holdings Group Inc. raised its position in GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after buying an additional 400 shares in the last quarter. 8.96% of the stock is currently owned by institutional investors.

Shares of GlaxoSmithKline PLC (NYSE GSK) opened at 38.79 on Friday. The firm’s 50-day moving average is $41.84 and its 200-day moving average is $41.84. The firm has a market cap of $94.80 billion, a P/E ratio of 37.51 and a beta of 1.03. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.59.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The business had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. On average, analysts anticipate that GlaxoSmithKline PLC will post $2.85 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be issued a $0.491 dividend. This represents a $1.96 dividend on an annualized basis and a yield of 5.06%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio is currently 197.00%.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline PLC (NYSE:GSK) Position Boosted by Keystone Financial Planning Inc.” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://theolympiareport.com/2017/08/12/glaxosmithkline-plc-nysegsk-position-boosted-by-keystone-financial-planning-inc.html.

A number of equities analysts have recently commented on the stock. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, July 24th. BidaskClub lowered shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Citigroup Inc. reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 27th. TheStreet lowered shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Finally, Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $46.00.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.